ArticleCancers2022
Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis.BMC cancer · 2023Pooled it
- Discordant Antitumor Efficacy with Compromised Survival in High-Risk Unresectable Hepatocellular Carcinoma.Cancers · 2026Article
- Predicting early progression to atezolizumab-bevacizumab in hepatocellular carcinoma: a clinical and imaging-based scoring system.European radiology · 2026Article
- Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Predictive Modeling and Mendelian Randomization for Identifying HCC Patients with High Response to TACE with Atezolizumab and Bevacizumab.Journal of hepatocellular carcinoma · 2026Article
- Atezolizumab Plus Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma: An Institutional Experience.Biomedicines · 2025Article
- Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.JHEP reports : innovation in hepatology · 2025Article
- Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors.NPJ biofilms and microbiomes · 2025Article
- Article
- Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence.JHEP reports : innovation in hepatology · 2025Article
- Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma-a multicentric study.BMC cancer · 2025Article
- Article
- Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Real-World Experience From a US Community Oncology Network.Journal of hepatocellular carcinoma · 2025Article
- Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report.World journal of clinical cases · 2024Article
- Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study.Liver cancer · 2024Article
- Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis.Liver cancer · 2024Article
- Article
- Systemic therapies in hepatocellular carcinoma: A revolution?United European gastroenterology journal · 2024Review
- A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2024Article
- Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?Journal of hepatocellular carcinoma · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of atezolizumab and bevacizumab (A + B) is the new standard of care for the systemic first-line treatment of hepatocellular carcinoma (HCC). However, up to now there are only few data on the safety and efficacy of A + B in real life. We included patients with advanced HCC treated with A + B as first-line therapy at four cancer centers in Germany and Austria between December 2018 and August 2021. Demographics, overall survival (OS), and adverse events were assessed until 15 September 2021. We included 66 patients. Most patients had compensated cirrhosis (n = 34; 52%), while Child-Pugh class B cirrhosis was observed in 23 patients (35%), and class C cirrhosis in 5 patients (8%). The best responses included a complete response (CR) in 7 patients (11%), a partial response (PR) in 12 patients (18%), stable disease (SD) in 22 patients (33%), and progressive disease in 11 patients (17%)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.